SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-------------------------------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): August 1, 2003
--------------
CYTOGEN CORPORATION
------------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
Delaware 000-14879 222322400
---------------------------- ------------------------ -------------------
(State or Other Jurisdiction (Commission File Number) (I.R.S. Employer
of Incorporation) Identification No.)
650 College Road East, CN 5308, Suite 3100, Princeton, NJ 08540
--------------------------------------------------------- ----------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (609) 750-8200
--------------
ITEM 5. OTHER EVENTS AND REQUIRED FD DISCLOSURE.
On August 1, 2003, Cytogen Corporation (the "Company") announced that
the Company completed the reacquisition of marketing rights held by Berlex
Laboratories, a U.S. affiliate of Schering AG, Germany, to QUADRAMET(R)
(Samarium Sm 153 Lexidronam) in North and Latin America, in exchange for an
upfront payment of $8 million and royalties based on future sales. QUADRAMET is
a skeletal targeting therapeutic radiopharmaceutical for the relief of pain due
to bone metastases arising from prostate, breast, multiple myeloma and other
types of cancer.
Such press release is attached hereto as Exhibit 99.1 and is
incorporated herein by reference. The foregoing description of such press
release is qualified in its entirety by reference to such document.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(c) Exhibits.
Exhibit No. Description
----------- -----------
99.1 Press release of the Company dated August 1, 2003.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this current report on Form 8-K to be signed on
its behalf by the undersigned hereunto duly authorized.
CYTOGEN CORPORATION
By: /s/ Michael D. Becker
----------------------------------
Michael D. Becker
President and Chief Executive
Officer
Dated: August 1, 2003
EXHIBIT INDEX
Exhibit No. Description
----------- -----------
99.1 Press release of the Company dated August 1, 2003.